Evaluation for Altitude-Associated Hypoxemia During Air Travel in Patients with Cardiopulmonary Disease (see High Altitude)

Clinical Data

• Comparative Study of 6MWT and Hypoxia Altitude Simulation Test (HAST) in Patients with Either Interstitial Lung Disease or COPD (Aviat Space Environ Med, 2007) [MEDLINE]
  • Oxygen Desaturation Induced by the 6MWT Correlated with that After HAST (r = 0.52)
• Study of Algorithm Using Resting/6WMT SpO2 and HAST in COPD Patients (Thorax, 2012) [MEDLINE]
  • Baseline SpO2 <92%: supplemental oxygen is required for air travel
  • Baseline SpO2 92-95%
    • 6MWT SpO2 <84%: supplemental oxygen is required for air travel
    • 6MWT SpO2 ≥84%:
      • HAST SpO2 ≤85%: supplemental oxygen is required for air travel
      • HAST SpO2 >85%: no supplemental oxygen is required for air travel
  • Baseline SpO2 >95%
    • 6MWT SpO2 <84%
      • HAST SpO2 ≤85%: supplemental oxygen is required for air travel
      • HAST SpO2 >85%: no supplemental oxygen is required for air travel
    • 6MWT SpO2 ≥84%: no supplemental oxygen is required for air travel

Evaluation of Chronic Obstructive Pulmonary Disease (COPD) (see Chronic Obstructive Pulmonary Disease)

• Clinical Efficacy
  • ECLIPSE Trial (2013) [MEDLINE]
    • 6MWT with a 30 m (98.4 ft) Decline in 6MWT Distance in the First Year was Associated with an Increased Risk for Mortality in the Subsequent 2 yrs
    • 6MWT Had No Significant Association with Frequency of Hospitalization Due to COPD Exacerbation
    • 6MWT Had a Weak Associations with Decline in FEV1
    • 6MWT Had a Weak Association with Decline in St George’s Respiratory Questionnaire (SGRQ) Criteria

Evaluation of Idiopathic Pulmonary Fibrosis (IPF) (see Idiopathic Pulmonary Fibrosis, [[Idiopathic Pulmonary Fibrosis]])

• xxxx [MEDLINE]

Evaluation of Pulmonary Hypertension (see Pulmonary Hypertension)

• xxxx